Bio-Techne's Ella Immunoassay Platform Receives CE-IVD Marking In EU
(RTTNews) - Bio-Techne Corp. (TECH) said its Ella benchtop immunoassay platform has received CE-IVD marking and is now available for clinical use across the European Union.
The CE-IVD certification allows hospitals, clinical laboratories and diagnostic developers in Europe to use the Ella platform for in-house test development, clinical trials and other translational applications. The company said the milestone expands Ella's use beyond research settings into clinical environments.
Bio-Techne said the CE-IVD marking supports its long-term strategy to advance precision diagnostics and standardized biomarker detection.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.